CPIG
SLDB icon

Chicago Partners Investment Group’s Solid Biosciences SLDB Stock Holding History

Chicago Partners Investment Group’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,266
Closed -$20K – 601
2021
Q4 		$20K Sell
1,266
-305
-19% -$9.32K ﹤0.01% 565
2021
Q3 		$51K Sell
1,571
-107
-6% -$4.54K ﹤0.01% 577
2021
Q2 		$70K Buy
1,678
+314
+23% +$20.7K 0.01% 523
2021
Q1 		$107K Buy
+1,364
New +$151K 0.01% 509

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Chicago Partners Investment Group's SLDB Position: Q1 2022 in Review

Chicago Partners Investment Group sold out of Solid Biosciences (SLDB) in Q1 2022, closing a stake of 1,266 shares — an estimated $20K sold.

Chicago Partners Investment Group first reported a position in SLDB in Q1 2021 and held it in 4 quarters. The position peaked at $107K in Q1 2021. 77 funds tracked by Wall St. Rank hold SLDB as of Q1 2022.

  • Chicago Partners Investment Group reported no remaining Solid Biosciences position as of Q1 2022 after selling out during the quarter.
  • Chicago Partners Investment Group sold 1,266 Solid Biosciences shares in Q1 2022, an estimated $20K.
  • Chicago Partners Investment Group first reported a position in Solid Biosciences in Q1 2021 and held it in 4 quarters.
  • Chicago Partners Investment Group's Solid Biosciences position peaked at $107K in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2022.

Based on Chicago Partners Investment Group's 13F filing for Q1 2022, filed 20 May 2022.